Amylin analysts advise caution amid stock run-up

Posted on March 28, 2012 at 16:59 PM EDT

Amylin Pharmaceuticals analysts are advising investors to proceed with caution given Wednesday’s massive run-up in the stock on a report that Bristol-Meyers had made a bid for the company.

Related Stocks:

AstraZeneca PLC ADS Bristol-Myers Squibb Co. Eli Lilly & Co. Forest Laboratories, Inc. GlaxoSmithKline PLC ADS Macys Merck & Co., Inc. Novo Nordisk A/S ADS Sanofi-Aventis ADS Takeda Pharmaceutical Co Ltd Sponsored ADR

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates